A Phase Ib open-label, multi-center, dose escalation trial of BI 764532 given as monotherapy administered by repeated intravenous infusions in patients with glioma expressing DLL3 (NCT05916313)
ADA, anti-drug antibodies; CNS, central nervous system; DLL3, delta-like canonical Notch ligand 3; DLT, dose-limiting toxicity; DoR, duration of response; KPS, IHC, immunohistochemistry; Karnofsky performance status; LCNEC, large-cell neuroendocrine carcinoma; MTD, maximum tolerated dose; nADA, neutralizing anti-drug antibodies; NEC, neuroendocrine carcinoma; ORR, objective response rate; PFS, progression-free survival; RANO, response assessment in neuro-oncology; WHO, World Health Organization.